Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**bupivacaine hydrochloride + povidone-iodine + methylprednisolone** is an unapproved small-molecule combination drug kit marketed under the brand name **Physicians EZ Use M-Pred** and associated with **Proficient Rx**. The kit combines **bupivacaine hydrochloride**, an amide local anesthetic that blocks voltage-gated sodium channels to inhibit nerve conduction and provide local or regional analgesia and anesthesia; **methylprednisolone** supplied as **methylprednisolone acetate**, a corticosteroid that activates glucocorticoid receptors to suppress inflammation; and **povidone-iodine**, a topical antiseptic included for procedural antisepsis. The product is used in procedural settings where anesthesia or analgesia and anti-inflammatory treatment are desired together, but the combination kit itself has been described as an **unapproved drug product** whose labeling has not been approved by the FDA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine hydrochloride + povidone-iodine + methylprednisolone.